Cardiomyocyte-specific CYP2J2 and its therapeutic implications

References

• Denisov IG, Makris TM, Sligar SG, et al. Structure and chemistry of cytochrome P450. Chem Rev. 2005 Jun;105(6):2253–2277.
   PubMed Web of Science ®Google Scholar
• Nebert DW, Wikvall K, Miller WL. Human cytochromes P450 in health and disease.Philos Trans R Soc Lond B Biol Sci. 2013 Feb 19:368(1612):20120431.
   PubMed Web of Science ®Google Scholar
• Jamieson KL, Endo T, Darwesh AM, et al. Cytochrome P450-derived eicosanoids and heart function. Pharmacol Ther. 2017 Nov;179:47–83.
   PubMed Web of Science ®Google Scholar
• Zuliani G, Galvani M, Leitersdorf E, et al. The role of polyunsaturated fatty acids (PUFA) in the treatment of dyslipidemias. Curr Pharm Des. 2009;15(36):4087–4093.
   PubMed Web of Science ®Google Scholar
• Calder PC. Polyunsaturated fatty acids, inflammation, and immunity. Lipids. 2001 Sep;36(9):1007–1024.
   PubMed Web of Science ®Google Scholar
• Wu S, Moomaw CR, Tomer KB, et al. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem. 1996 Feb 16:271(7):3460–3468.
   PubMed Web of Science ®Google Scholar
• Ma J, Ramachandran S, Fiedorek FTsJr., et al. Mapping of the CYP2J cytochrome P450 genes to human chromosome 1 and mouse chromosome 4. Genomics. 1998 Apr 1:49(1):152–155.
   PubMed Web of Science ®Google Scholar
• King LM, Ma J, Srettabunjong S, et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol. 2002 Apr;61(4):840–852.
   PubMed Web of Science ®Google Scholar
• Cong S, Ma XT, Li YX, et al. Structural basis for the mutation-induced dysfunction of human CYP2J2: a computational study. J Chem Inf Model. 2013 Jun 24:53(6):10124–10143.
   Web of Science ®Google Scholar
• Proietti G, Abelak KK, Bishop-Bailey D, et al. Computational modelling of the binding of arachidonic acid to the human monooxygenase CYP2J2. J Mol Model. 2016 Nov;22(11):279.
   PubMed Web of Science ®Google Scholar
• Marden NY, Fiala-Beer E, Xiang SH, et al. Role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia. Biochem J. 2003 Aug 1:373(3):669–680.
   PubMedGoogle Scholar
• Marden NY, Murray M. Characterization of a c-Jun-responsive module in the 5′-flank of the human CYP2J2 gene that regulates transactivation. Biochem J. 2005 Nov 1:391(3):631–640.
   PubMedGoogle Scholar
• Cui PH, Lee AC, Zhou F, et al. Impaired transactivation of the human CYP2J2 arachidonic acid epoxygenase gene in HepG2 cells subjected to nitrative stress. Br J Pharmacol. 2010 Apr;159(7):1440–1449.
   PubMed Web of Science ®Google Scholar
• Murray M. CYP2J2 – regulation, function and polymorphism. Drug Metab Rev. 2016 Aug;48(3):351–368.
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Baker DW, Totah RA, et al. Variability of CYP2J2 expression in human fetal tissues. J Pharmacol Exp Ther. 2006 Nov;319(2):523–532.
   PubMed Web of Science ®Google Scholar
• Chen F, Chen C, Yang S, et al. Let-7b inhibits human cancer phenotype by targeting cytochrome P450 epoxygenase 2J2. Plos One. 2012;7(6):e39197.
   PubMed Web of Science ®Google Scholar
• Park JW, Lee CM, Cheng JS, et al. Posttranslational regulation of CYP2J2 by nitric oxide. Free Radic Biol Med. 2018 Jun;121:149–156.
   PubMed Web of Science ®Google Scholar
• Hornbeck PV, Zhang B, Murray B, et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 2015 Jan;43(D1):D512–20.
   PubMed Web of Science ®Google Scholar
• Enayetallah AE, French RA, Thibodeau MS, et al. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem. 2004 Apr;52(4):447–454.
   PubMed Web of Science ®Google Scholar
• Dutheil F, Dauchy S, Diry M, et al. Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos. 2009 Jul;37(7):1528–1538.
   PubMed Web of Science ®Google Scholar
• Wu S, Chen W, Murphy E, et al. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem. 1997 May 9:272(19):12551–12559.
   PubMed Web of Science ®Google Scholar
• Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999 Aug 20:285(5431):1276–1279.
   PubMed Web of Science ®Google Scholar
• Delozier TC, Kissling GE, Coulter SJ, et al. Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos. 2007 Apr;35(4):682–688.
   PubMed Web of Science ®Google Scholar
• Bystrom J, Wray JA, Sugden MC, et al. Endogenous epoxygenases are modulators of monocyte/macrophage activity. Plos One. 2011;6(10):e26591.
   PubMed Web of Science ®Google Scholar
• Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease. Nat Rev Immunol. 2018 Dec;18(12):733–744.
   PubMed Web of Science ®Google Scholar
• Edin ML, Wang Z, Bradbury JA, et al. Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. FASEB J. 2011 Oct;25(10):3436–3447.
   PubMed Web of Science ®Google Scholar
• Fleming I, Michaelis UR, Bredenkotter D, et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res. 2001 Jan 19:88(1):44–51.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Okayama A, Imai N, et al. Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica. 2006 Dec;36(12):1201–1209.
   PubMed Web of Science ®Google Scholar
• Evangelista EA, Kaspera R, Mokadam NA, et al. Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes. Drug Metab Dispos. 2013 Dec;41(12):2087–2094.
   PubMed Web of Science ®Google Scholar
• Evangelista EA, Aliwarga T, Sotoodehnia N, et al. CYP2J2 modulates diverse transcriptional programs in adult human cardiomyocytes. Sci Rep. 2020 Mar 24:10(1):5329.
   PubMed Web of Science ®Google Scholar
• Cizkova K, Tauber Z. Time-dependent expression pattern of cytochrome P450 epoxygenases and soluble epoxide hydrolase in normal human placenta. Acta Histochem. 2018 Aug;120(6):513–519.
   PubMed Web of Science ®Google Scholar
• Jiang JG, Chen CL, Card JW, et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 2005 Jun 1:65(11):4707–4715.
   PubMed Web of Science ®Google Scholar
• Zhou C, Huang J, Li Q, et al. CYP2J2-derived EETs attenuated ethanol-induced myocardial dysfunction through inducing autophagy and reducing apoptosis. Free Radic Biol Med. 2018 Mar;117:168–179.
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018 Nov 13:138(20):e618–e651.
   PubMed Web of Science ®Google Scholar
• Seubert J, Yang B, Bradbury JA, et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res. 2004 Sep 3:95(5):506–514.
   PubMed Web of Science ®Google Scholar
• Aliwarga T, Guo X, Evangelista EA, et al. Higher epoxyeicosatrienoic acids in cardiomyocytes-specific CYP2J2 transgenic mice are associated with improved myocardial remodeling. Biomedicines. 2020 May 30:8(6):144.
   PubMed Web of Science ®Google Scholar
• Chaudhary KR, Zordoky BN, Edin ML, et al. Differential effects of soluble epoxide hydrolase inhibition and CYP2J2 overexpression on postischemic cardiac function in aged mice. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:8–17.
   PubMed Web of Science ®Google Scholar
• Samokhvalov V, Jamieson KL, Darwesh AM, et al. Deficiency of soluble epoxide hydrolase protects cardiac function impaired by LPS-induced acute inflammation. Front Pharmacol. 2018;9:1572.
   PubMed Web of Science ®Google Scholar
• Bannehr M, Lohr L, Gelep J, et al. Linoleic acid metabolite DiHOME decreases post-ischemic cardiac recovery in murine hearts. Cardiovasc Toxicol. 2019 Aug;19(4):365–371.
   PubMed Web of Science ®Google Scholar
• Zhang Y, El-Sikhry H, Chaudhary KR, et al. Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H37–46.
   PubMed Web of Science ®Google Scholar
• Evangelista EA, Lemaitre RN, Sotoodehnia N, et al. CYP2J2 expression in adult ventricular myocytes protects against reactive oxygen species toxicity. Drug Metab Dispos. 2018 Apr;46(4):380–386.
   PubMed Web of Science ®Google Scholar
• Solanki M, Pointon A, Jones B, et al. Cytochrome P450 2J2: potential role in drug metabolism and cardiotoxicity. Drug Metab Dispos. 2018 Aug;46(8):1053–1065.
   PubMed Web of Science ®Google Scholar
• Das A, Weigle AT, Arnold WR, et al. CYP2J2 molecular recognition: a new axis for therapeutic design. Pharmacol Ther. 2020 Nov;215:107601.
   PubMed Web of Science ®Google Scholar
• Michaud V, Frappier M, Dumas M-C, et al. Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism. PLoS One. 2010 Dec 14:5(12):e15666.
   PubMed Web of Science ®Google Scholar
• Kang W, Elitzer S, Noh K, et al. Myocardial pharmacokinetics of ebastine, a substrate for cytochrome P450 2J, in rat isolated heart. Br J Pharmacol. 2011 Aug;163(8):1733–1739.
   PubMed Web of Science ®Google Scholar
• DuBuske LM. Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther. 1999 Feb;21(2):281–295.
   PubMed Web of Science ®Google Scholar
• Narjoz C, Favre A, McMullen J, et al. Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance. PLoS One. 2014;9(5):e95532.
   PubMed Web of Science ®Google Scholar
• Arnold WR, Baylon JL, Tajkhorshid E, et al. Arachidonic acid metabolism by human cardiovascular CYP2J2 is modulated by doxorubicin. Biochemistry. 2017 Dec 26:56(51):6700–6712.
   PubMed Web of Science ®Google Scholar
• Heusch G, Libby P, Gersh B, et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. 2014 May 31:383(9932):1933–1943.
   PubMed Web of Science ®Google Scholar
• Lai J, Chen C. The role of epoxyeicosatrienoic acids in cardiac remodeling. Front Physiol. 2021;12:642470.
   PubMed Web of Science ®Google Scholar
• Wang X, Ni L, Yang L, et al. CYP2J2-derived epoxyeicosatrienoic acids suppress endoplasmic reticulum stress in heart failure. Mol Pharmacol. 2014 Jan;85(1):105–115.
   PubMed Web of Science ®Google Scholar
• Yang L, Ni L, Duan Q, et al. CYP epoxygenase 2J2 prevents cardiac fibrosis by suppression of transmission of pro-inflammation from cardiomyocytes to macrophages. Prostaglandins Other Lipid Mediat. 2015 Jan-Mar;116-117:64–75.
   PubMed Web of Science ®Google Scholar
• He Z, Zhang X, Chen C, et al. Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II. Cardiovasc Res. 2015 Mar 1:105(3):304–317.
   PubMed Web of Science ®Google Scholar
• He Z, Yang Y, Wen Z, et al. CYP2J2 metabolites, epoxyeicosatrienoic acids, attenuate Ang II-induced cardiac fibrotic response by targeting Galpha12/13. J Lipid Res. 2017 Jul;58(7):1338–1353.
   PubMed Web of Science ®Google Scholar
• Nattel S. Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation. JACC Clin Electrophysiol. 2017 May;3(5):425–435.
   PubMedGoogle Scholar
• Ke Q, Xiao YF, Bradbury JA, et al. Electrophysiological properties of cardiomyocytes isolated from CYP2J2 transgenic mice. Mol Pharmacol. 2007 Oct;72(4):1063–1073.
   PubMed Web of Science ®Google Scholar
• Xiao YF, Ke Q, Seubert JM, et al. Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2. Mol Pharmacol. 2004 Dec;66(6):1607–1616.
   PubMed Web of Science ®Google Scholar
• Westphal C, Spallek B, Konkel A, et al. CYP2J2 overexpression protects against arrhythmia susceptibility in cardiac hypertrophy. Plos One. 2013;8(8):e73490.
   PubMed Web of Science ®Google Scholar
• Li X, Zhu F, Meng W, et al. CYP2J2/EET reduces vulnerability to atrial fibrillation in chronic pressure overload mice. J Cell Mol Med. 2020 Jan;24(1):862–874.
   PubMed Web of Science ®Google Scholar
• Arnold C, Markovic M, Blossey K, et al. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of {omega}-3 fatty acids. J Biol Chem. 2010 Oct 22:285(43):32720–32733.
   PubMed Web of Science ®Google Scholar
• Lu T, VanRollins M, Lee HC. Stereospecific activation of cardiac ATP-sensitive K(+) channels by epoxyeicosatrienoic acids: a structural determinant study. Mol Pharmacol. 2002 Nov;62(5):1076–1083.
   PubMed Web of Science ®Google Scholar
• Martin L, Derwall M, Al Zoubi S, et al. The septic heart: current understanding of molecular mechanisms and clinical implications. Chest. 2019 Feb;155(2):427–437.
   PubMed Web of Science ®Google Scholar
• Epelman S, Liu PP, Mann DL. Role of innate and adaptive immune mechanisms in cardiac injury and repair. Nat Rev Immunol. 2015 Feb;15(2):117–129.
   PubMed Web of Science ®Google Scholar
• Zhao G, Wang J, Xu X, et al. Epoxyeicosatrienoic acids protect rat hearts against tumor necrosis factor-alpha-induced injury. J Lipid Res. 2012 Mar;53(3):456–466.
   PubMed Web of Science ®Google Scholar
• Dai M, Wu L, He Z, et al. Epoxyeicosatrienoic acids regulate macrophage polarization and prevent LPS-induced cardiac dysfunction. J Cell Physiol. 2015 Sep;230(9):2108–2119.
   PubMed Web of Science ®Google Scholar
• Zhao G, Wang X, Edwards S, et al. NLRX1 knockout aggravates lipopolysaccharide (LPS)-induced heart injury and attenuates the anti-LPS cardioprotective effect of CYP2J2/11,12-EET by enhancing activation of NF-kappaB and NLRP3 inflammasome. Eur J Pharmacol. 2020 Aug 15:881:173276.
   PubMed Web of Science ®Google Scholar
• Samokhvalov V, Jamieson KL, Vriend J, et al. CYP-epoxygenase metabolites of docosahexaenoic acid protect HL-1 cardiac cells against LPS-induced cytotoxicity through SIRT1. Cell Death Discov. 2015 Nov 23:1(1). 10.1038/cddiscovery.2015.54.
   PubMedGoogle Scholar
• Panigrahy D, Edin ML, Lee CR, et al. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest. 2012 Jan;122(1):178–191.
   PubMed Web of Science ®Google Scholar
• Karkhanis A, Hong Y, Chan ECY. Inhibition and inactivation of human CYP2J2: implications in cardiac pathophysiology and opportunities in cancer therapy. Biochem Pharmacol. 2017 Jul 1:135:12–21
   PubMed Web of Science ®Google Scholar
• Park SH, Phuc NM, Lee J, et al. Identification of acetylshikonin as the novel CYP2J2 inhibitor with anti-cancer activity in HepG2 cells. Phytomedicine. 2017 Jan 15:24:134–140.
   PubMed Web of Science ®Google Scholar
• Karkhanis A, Tram NDT, Chan ECY. Effects of dronedarone, amiodarone and their active metabolites on sequential metabolism of arachidonic acid to epoxyeicosatrienoic and dihydroxyeicosatrienoic acids. Biochem Pharmacol. 2017 Dec 15:146:188–198
   PubMed Web of Science ®Google Scholar
• Lafite P, Dijols S, Zeldin DC, et al. Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2. Arch Biochem Biophys. 2007 Aug 15:464(2):155–168.
   PubMed Web of Science ®Google Scholar
• Lee CM, Lee J, Jang SN, et al. 6,8-diprenylorobol induces apoptosis in human hepatocellular carcinoma cells via activation of FOXO3 and inhibition of CYP2J2. Oxid Med Cell Longev. 2020;2020:8887251.
   PubMed Web of Science ®Google Scholar
• Lafite P, Dijols S, Buisson D, et al. Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2. Bioorg Med Chem Lett. 2006 May 15:16(10):2777–2780.
   PubMed Web of Science ®Google Scholar
• Chen C, Li G, Liao W, et al. Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J Pharmacol Exp Ther. 2009 Jun;329(3):908–918.
   PubMed Web of Science ®Google Scholar
• Karkhanis A, Leow JWH, Hagen T, et al. Dronedarone-induced cardiac mitochondrial dysfunction and its mitigation by epoxyeicosatrienoic acids. Toxicol Sci. 2018 May 1:163(1):79–91.
   PubMed Web of Science ®Google Scholar
• Lee CA, Jones JPs3rd, Katayama J, et al. Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab Dispos. 2012 May;40(5):943–951.
   PubMed Web of Science ®Google Scholar
• Ren S, Zeng J, Mei Y, et al. Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors. Drug Metab Dispos. 2013 Jan;41(1):60–71.
   PubMed Web of Science ®Google Scholar
• Lee E, Wu Z, Shon JC, et al. Danazol inhibits cytochrome P450 2J2 activity in a substrate-independent manner. Drug Metab Dispos. 2015 Aug;43(8):1250–1253.
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008 Jun 19:358(25):2678–2687.
   PubMed Web of Science ®Google Scholar
• Karkhanis A, Lam HY, Venkatesan G, et al. Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites. Biochem Pharmacol. 2016 May 1:107:67–80.
   PubMed Web of Science ®Google Scholar
• Lin HL, Zhang H, Walker VJ, et al. Heme modification contributes to the mechanism-based inactivation of human cytochrome P450 2J2 by two terminal acetylenic compounds. Drug Metab Dispos. 2017 Sep;45(9):990–999.
   PubMed Web of Science ®Google Scholar
• Jeon YJ, Kim JS, Hwang GH, et al. Inhibition of cytochrome P450 2J2 by tanshinone IIA induces apoptotic cell death in hepatocellular carcinoma HepG2 cells. Eur J Pharmacol. 2015 Oct 5:764:480–488.
   PubMed Web of Science ®Google Scholar
• Lee B, Wu Z, Sung SH, et al. Potential of decursin to inhibit the human cytochrome P450 2J2 isoform. Food Chem Toxicol. 2014 Aug;70:94–99.
   PubMed Web of Science ®Google Scholar
• Park SH, Lee J, Shon JC, et al. The inhibitory potential of broussochalcone A for the human cytochrome P450 2J2 isoform and its anti-cancer effects via FOXO3 activation. Phytomedicine. 2018 Mar 15:42:199–206.
   PubMed Web of Science ®Google Scholar
• Lu J, Liu D, Zhou X, et al. Plant natural product plumbagin presents potent inhibitory effect on human cytochrome P450 2J2 enzyme. Phytomedicine. 2018 Jan 15:39:137–145.
   PubMed Web of Science ®Google Scholar
• Lin HL, Zhang H, Hollenberg PF. Formation of both heme and apoprotein adducts contributes to the mechanism-based inactivation of human CYP2J2 by 17alpha-Ethynylestradiol. Drug Metab Dispos. 2018 Jun;46(6):813–822.
   PubMed Web of Science ®Google Scholar
• Leow JWH, Verma RK, Lim ABH, et al. Atypical kinetics of cytochrome P450 2J2: epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors. Eur J Pharm Sci. 2021 Sep 1:164:105889.
   PubMed Web of Science ®Google Scholar
• Huang X, Wang Y, Wang Y, et al. Ophiopogonin D reduces myocardial ischemia-reperfusion injury via upregulating CYP2J3/EETs in rats. Cell Physiol Biochem. 2018;49(4):1646–1658.
   PubMedGoogle Scholar
• Cannata A, Ali H, Sinagra G, et al. Gene therapy for the heart lessons learned and future perspectives. Circ Res. 2020 May 8:126(10):1394–1414.
   PubMed Web of Science ®Google Scholar
• Davydov DR, Halpert JR. Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both? Expert Opin Drug Metab Toxicol. 2008 Dec;4(12):1523–1535.
   PubMed Web of Science ®Google Scholar
• Xu L, Chen LY. Molecular determinant of substrate binding and specificity of cytochrome P450 2J2. Sci Rep. 2020 Dec 17:10(1):22267.
   PubMed Web of Science ®Google Scholar
• Zhang G, Panigrahy D, Mahakian LM, et al. Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A. 2013 Apr 16:110(16):1027–1031.
   Web of Science ®Google Scholar
• Wei B, You MG, Ling JJ, et al. Regulation of antioxidant system, lipids and fatty acid beta-oxidation contributes to the cardioprotective effect of sodium tanshinone IIA sulphonate in isoproterenol-induced myocardial infarction in rats. Atherosclerosis. 2013 Sep;230(1):148–156.
   PubMed Web of Science ®Google Scholar
• Berlin DS, Sangkuhl K, Klein TE, et al. PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2. Pharmacogenet Genomics. 2011 May;21(5):308–311.
   PubMed Web of Science ®Google Scholar
• Kang X, Shi H, Zhang L, et al. Genetic polymorphisms of CYP2S1, CYP2J2 and CYP2R1 genes in three Chinese populations: Han, Tibetan and Uighur. Pharmacogenomics. 2018 Aug 1:19(12):961–977.
   PubMed Web of Science ®Google Scholar
• Lee SS, Jeong HE, Liu KH, et al. Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenet Genomics. 2005 Feb;15(2):105–113.
   PubMed Web of Science ®Google Scholar
• Spiecker M, Darius H, Hankeln T, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation. 2004 Oct 12:110(15):2132–2136.
   PubMed Web of Science ®Google Scholar
• Polonikov AV, Ivanov VP, Solodilova MA, et al. A common polymorphism G-50T in cytochrome P450 2J2 gene is associated with increased risk of essential hypertension in a Russian population. Dis Markers. 2008;24(2):119–126.
   PubMed Web of Science ®Google Scholar
• Wu SN, Zhang Y, Gardner CO, et al. Evidence for association of polymorphisms in CYP2J2 and susceptibility to essential hypertension. Ann Hum Genet. 2007 Jul;71(4):519–525.
   PubMedGoogle Scholar
• Borgel J, Bulut D, Hanefeld C, et al. The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile. BMC Cardiovasc Disord. 2008 Dec 23:8(1):41.
   PubMedGoogle Scholar
• Zhang L, Ding H, Yan J, et al. Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and risk of ischemic stroke in a Chinese population. Pharmacogenet Genomics. 2008 Jan;18(1):45–51.
   PubMed Web of Science ®Google Scholar
• Xu Y, Ding H, Peng J, et al. Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease. Pharmacogenet Genomics. 2011 Aug;21(8):489–494.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Fu Z, Ma Y, et al. A novel polymorphism of the CYP2J2 gene is associated with coronary artery disease in Uygur population in China. Clin Biochem. 2013 Aug;46(12):1047–1054.
   PubMed Web of Science ®Google Scholar
• Liu PY, Li YH, Chao TH, et al. Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis. 2007 Nov;195(1):199–206.
   PubMed Web of Science ®Google Scholar
• Marciante KD, Totah RA, Heckbert SR, et al. Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke. Pharmacogenet Genomics. 2008 Jun;18(6):535–543.
   PubMed Web of Science ®Google Scholar
• Dreisbach AW, Japa S, Sigel A, et al. The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens. 2005 Oct;18(10):1276–1281.
   PubMed Web of Science ®Google Scholar
• King LM, Gainer JV, David GL, et al. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics. 2005 Jan;15(1):7–13.
   PubMedGoogle Scholar
• Lee CR, North KE, Bray MS, et al. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet Genomics. 2007 May;17(5):349–358.
   PubMed Web of Science ®Google Scholar
• Fava C, Montagnana M, Almgren P, et al. The common functional polymorphism −50G>T of the CYP2J2 gene is not associated with ischemic coronary and cerebrovascular events in an urban-based sample of Swedes. J Hypertens. 2010 Feb;28(2):294–299.
   PubMed Web of Science ®Google Scholar
• Alghasham A, Ali A, Ismail H, et al. CYP2J2 −50 G/T and ADRB2 G46A gene polymorphisms in Saudi subjects with hypertension. Genet Test Mol Biomarkers. 2012 Sep;16(9):1027–1031.
   PubMed Web of Science ®Google Scholar
• Isensee J, Witt H, Pregla R, et al. Sexually dimorphic gene expression in the heart of mice and men. J Mol Med (Berl). 2008 Jan;86(1):61–74.
   PubMed Web of Science ®Google Scholar
• Polonikov AV, Ponomarenko IV, Bykanova MA, et al. A comprehensive study revealed SNP-SNP interactions and a sex-dependent relationship between polymorphisms of the CYP2J2 gene and hypertension risk. Hypertens Res. 2019 Feb;42(2):257–272.
   PubMed Web of Science ®Google Scholar
• McDougle DR, Kambalyal A, Meling DD, et al. Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase. J Pharmacol Exp Ther. 2014 Dec;351(3):616–627.
   PubMed Web of Science ®Google Scholar
• Moran JH, Mitchell LA, Bradbury JA, et al. Analysis of the cytotoxic properties of linoleic acid metabolites produced by renal and hepatic P450s. Toxicol Appl Pharmacol. 2000 Nov 1:168(3):268–279.
   PubMed Web of Science ®Google Scholar
• Aiba I, Yamasaki T, Shinki T, et al. Characterization of rat and human CYP2J enzymes as vitamin D 25-hydroxylases. Steroids. 2006 Oct;71(10):849–856.
   PubMed Web of Science ®Google Scholar
• Lee CA, Neul D, Clouser-Roche A, et al. Identification of novel substrates for human cytochrome P450 2J2. Drug Metab Dispos. 2010 Feb;38(2):347–356.
   PubMed Web of Science ®Google Scholar
• Wu Z, Lee D, Joo J, et al. CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems. Antimicrob Agents Chemother. 2013 Nov;57(11):5448–5456.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Hirama T, Matsubara T, et al. Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos. 2002 Nov;30(11):1240–1245.
   PubMed Web of Science ®Google Scholar
• Hashizume T, Imaoka S, Mise M, et al. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther. 2002 Jan;300(1):298–304.
   PubMed Web of Science ®Google Scholar
• Kaspera R, Kirby BJ, Sahele T, et al. Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo. Biochem Pharmacol. 2014 Sep 1:91(1):109–118.
   PubMed Web of Science ®Google Scholar
• Ghosal A, Lu X, Penner N, et al. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab Dispos. 2011 Jan;39(1):30–38.
   PubMed Web of Science ®Google Scholar
• Arnold WR, Weigle AT, Das A. Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2. J Inorg Biochem. 2018 Jul;184:88–99.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang R, Li J, et al. Stable EET urea agonist and soluble epoxide hydrolase inhibitor regulate rat pulmonary arteries through TRPCs. Hypertens Res. 2011 May;34(5):630–639.
   PubMed Web of Science ®Google Scholar
• Khan MA, Liu J, Kumar G, et al. Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity. FASEB J. 2013 Aug;27(8):2946–2956.
   PubMed Web of Science ®Google Scholar
• Adebesin AM, Wesser T, Vijaykumar J, et al. Development of robust 17(R),18(S)-Epoxyeicosatetraenoic acid (17,18-EEQ) analogues as potential clinical antiarrhythmic agents. J Med Chem. 2019 Nov 27:62(22):10124–10143.
   PubMed Web of Science ®Google Scholar
• Dyari HRE, Rawling T, Chen Y, et al. A novel synthetic analogue of omega-3 17,18-epoxyeicosatetraenoic acid activates TNF receptor-1/ASK1/JNK signaling to promote apoptosis in human breast cancer cells. FASEB J. 2017 Dec;31(12):5246–5257.
   PubMed Web of Science ®Google Scholar
• Darwesh AM, Bassiouni W, Adebesin AM, et al. A synthetic epoxydocosapentaenoic acid analogue ameliorates cardiac ischemia/reperfusion injury: the involvement of the sirtuin 3-NLRP3 pathway. Int J Mol Sci. 2020 Jul 24:21(15):5261.
   Web of Science ®Google Scholar
• Liu Y, Zhang Y, Schmelzer K, et al. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A. 2005 Nov 15:102(46):16747–16752.
   PubMed Web of Science ®Google Scholar
• Lu T, Ye D, Wang X, et al. Cardiac and vascular K ATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms. J Physiol. 2006 Sep 1:575(2):627–644.
   PubMed Web of Science ®Google Scholar
• Park SK, Herrnreiter A, Pfister SL, et al. GPR40 is a low-affinity epoxyeicosatrienoic acid receptor in vascular cells. J Biol Chem. 2018 Jul 6:293(27):10675–10691.
   PubMed Web of Science ®Google Scholar